View More Recent Stories
-
Travere Therapeutics (TVTX) PT Raised to $13 at Stifel
-
Travere Therapeutics (TVTX) PT Lowered to $22 at Canaccord Genuity
-
Travere Therapeutics (TVTX) PT Raised to $18 at Barclays
-
TD Cowen Reiterates Buy Rating on Travere Therapeutics (TVTX)
-
Travere Therapeutics (TVTX) PT Lowered to $19 at Citi
-
Travere Therapeutics (TVTX) PT Lowered to $18 at H.C. Wainwright
-
Travere Therapeutics (TVTX) PT Lowered to $18 at BofA Securities
-
After-hours movers: Costco, Scholastic Corp, Travere Therapeutics
-
Travere Therapeutics (TVTX) Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase
-
Travere Therapeutics (TVTX) PT Raised to $23 at Canaccord Genuity
-
Travere Therapeutics (TVTX) PT Raised to $23 at Citi, 'Full Approval as Expected and We Expect Positive Inflection in Sales Trajectory'
-
Travere Therapeutics (TVTX) PT Raised to $23 at H.C. Wainwright
-
Travere Therapeutics (TVTX) PT Raised to $19 at BofA Securities
-
Travere Therapeutics (TVTX) Halted, News Pending
-
Piper Sandler Reiterates Neutral Rating on Travere Therapeutics (TVTX)
-
Travere Therapeutics (TVTX) PT Raised to $12 at Piper Sandler
-
Travere Therapeutics (TVTX) Tops Q2 EPS by 14c

